/
HROW
$41.15-$0.92 (-2.19%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.6B
37M shares
52-week range
$28.54 – $54.85
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.66%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$31.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.4M | $51.2M | $48.9M | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Cost of revenue | $16.5M | $16.7M | $14.5M | $18.2M | $25.4M | $39.6M | $49.2M | $67.9M |
| Gross profit | $24.9M | $34.4M | $34.4M | $54.3M | $63.2M | $90.6M | $150.4M | $204.4M |
| Gross margin | 60.1% | 67.3% | 70.4% | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| R&D | $825.0K | $2.1M | $2.4M | $11.1M | $3.0M | $6.7M | $12.2M | $12.8M |
| Operating income | −$5.2M | −$4.8M | $385.0K | $1.6M | $1.9M | $431.0K | $8.8M | $38.6M |
| EBITDA | −$3.4M | $1.9M | $2.6M | $5.1M | −$3.9M | $11.9M | $22.1M | $41.4M |
| Net income | $14.6M | $168.0K | −$3.4M | −$18.0M | −$14.1M | −$24.4M | −$17.5M | −$5.1M |
| Net margin | 35.3% | 0.3% | -6.9% | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| EPS (diluted) | 0.61 | 0.01 | -0.13 | -0.69 | -0.51 | -0.75 | -0.49 | -0.14 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $348M | $0.25 | $0.13–$0.48 | 5 |
| 2027 | $516M | $2.31 | $1.22–$3.22 | 5 |
| 2028 | $707M | $3.96 | $2.87–$5.05 | 2 |
| 2029 | $959M | $6.85 | $6.27–$7.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Harrow, Inc. Common Stock
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
www.harrow.com- Employees
- 373
- IPO / List date
- Apr 30, 2007
- HQ
- NASHVILLE, TN
Held by traders on TradeandTell
No one on the platform currently holds HROW.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 84,579 | $3.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-02-08 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded HROW yet.
